Triptolide inhibits tumor growth by induction of cellular senescence

Li,Ruidong; Zhang,Xiaofei; Tian,Xiaoying; Shen,Conghuan; Zhang,Quanbao; Zhang,Yihong; Wang,Zhengxin; Wang,Feifei; Tao,Yifeng

doi:10.3892/or.2016.5258

Triptolide inhibits tumor growth by induction of cellular senescence

Authors:
- Ruidong Li
- Xiaofei Zhang
- Xiaoying Tian
- Conghuan Shen
- Quanbao Zhang
- Yihong Zhang
- Zhengxin Wang
- Feifei Wang
- Yifeng Tao
View Affiliations

Affiliations: Department of General Surgery and Liver Transplant Center, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Bioscience Research Center, Shanghai 200120, P.R. China
Published online on: November 18, 2016 https://doi.org/10.3892/or.2016.5258
Pages: 442-448

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cellular senescence, an irreversible growth arrest of cells, is involved in protection against cancer. Triptolide (TPL) plays an important role in immunosuppressive, anti-fertility, anti-cystogenesis and anticancer activities. However, effect and mechanism of TPL on cellular senescence-associated antitumor is rarely reported. Herein HepG2 cells were used to explore the effect of TPL on tumor growth and cellular senescence. We showed that TPL inhibited tumor cell proliferation and growth in vitro and in vivo, accelerated cellular senescence and arrested cells at G0/G1 phase. We further demonstrated that TPL accelerated HepG2 cell senescence by regulating the AKT pathway. In addition, TPL could also enhance cellular senescence and inhibit tumor growth by negatively regulating human telomerase reverse transcriptase (hTERT) signaling pathway. These findings reveal a regulatory mechanism of TPL on cellular senescence, indicating that TPL promotes HepG2 cell senescence through AKT pathway and hTERT pathway simultaneously. Altogether, TPL-induced senescence can be regarded as a promising strategy for anticancer therapy and drug development.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hayflick L and Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res. 25:585–621. 1961. View Article : Google Scholar : PubMed/NCBI
3	Collado M and Serrano M: Senescence in tumours: Evidence from mice and humans. Nat Rev Cancer. 10:51–57. 2010. View Article : Google Scholar : PubMed/NCBI
4	Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T and Schmitt CA: Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 436:660–665. 2005. View Article : Google Scholar : PubMed/NCBI
5	Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, et al: Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 444:633–637. 2006. View Article : Google Scholar : PubMed/NCBI
6	Rufini A, Tucci P, Celardo I and Melino G: Senescence and aging: The critical roles of p53. Oncogene. 32:5129–5143. 2013. View Article : Google Scholar : PubMed/NCBI
7	Provinciali M, Cardelli M, Marchegiani F and Pierpaoli E: Impact of cellular senescence in aging and cancer. Curr Pharm Des. 19:1699–1709. 2013. View Article : Google Scholar : PubMed/NCBI
8	Nardella C, Clohessy JG, Alimonti A and Pandolfi PP: Pro-senescence therapy for cancer treatment. Nat Rev Cancer. 11:503–511. 2011. View Article : Google Scholar : PubMed/NCBI
9	Acosta JC and Gil J: Senescence: A new weapon for cancer therapy. Trends Cell Biol. 22:211–219. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kupchan SM, Court WA, Dailey RG Jr, Gilmore CJ and Bryan RF: Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc. 94:7194–7195. 1972. View Article : Google Scholar : PubMed/NCBI
11	Sun L, Li H, Huang X, Wang T, Zhang S, Yang J, Huang S, Mei H, Jiang Z and Zhang L: Triptolide alters barrier function in renal proximal tubular cells in rats. Toxicol Lett. 223:96–102. 2013. View Article : Google Scholar : PubMed/NCBI
12	Reno TA, Kim JY and Raz DJ: Triptolide inhibits lung cancer cell migration, invasion, and metastasis. Ann Thorac Surg. 100:1817–1824; discussion 1824–1815. 2015. View Article : Google Scholar : PubMed/NCBI
13	Jiang XH, Wong BC, Lin MC, Zhu GH, Kung HF, Jiang SH, Yang D and Lam SK: Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 20:8009–8018. 2001. View Article : Google Scholar : PubMed/NCBI
14	Li C, Xing G, Maeda K, Wu C, Gong L, Sugiyama Y, Qi X, Ren J and Wang G: The role of breast cancer resistance protein (Bcrp/Abcg2) in triptolide-induced testis toxicity. Toxicol Res. 4:1260–1268. 2015. View Article : Google Scholar
15	Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, Yang J, Underhill CB and Zhang L: Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther. 2:65–72. 2003.PubMed/NCBI
16	Wang Z, Jin H, Xu R, Mei Q and Fan D: Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med. 41:717–727. 2009. View Article : Google Scholar : PubMed/NCBI
17	Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM and Saluja AK: Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 67:9407–9416. 2007. View Article : Google Scholar : PubMed/NCBI
18	Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, Haupt Y, Hannan RD and Pearson RB: AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: Implications for targeting mTOR during malignancy. Oncogene. 31:1949–1962. 2012. View Article : Google Scholar : PubMed/NCBI
19	Sin S, Kim SY and Kim SS: Chronic treatment with ginsenoside Rg3 induces Akt-dependent senescence in human glioma cells. Int J Oncol. 41:1669–1674. 2012.PubMed/NCBI
20	Reno TA, Tong SW, Wu J, Fidler JM, Nelson R, Kim JY and Raz DJ: The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer. BMC Cancer. 16:4392016. View Article : Google Scholar : PubMed/NCBI
21	Collado M, Blasco MA and Serrano M: Cellular senescence in cancer and aging. Cell. 130:223–233. 2007. View Article : Google Scholar : PubMed/NCBI
22	Dimitrova V and Arcaro A: Targeting the PI3K/AKT/mTOR signaling pathway in medulloblastoma. Curr Mol Med. 15:82–93. 2015. View Article : Google Scholar : PubMed/NCBI
23	Park JH, Kim JJ and Bae YS: Involvement of PI3K-AKT-mTOR pathway in protein kinase CKII inhibition-mediated senescence in human colon cancer cells. Biochem Biophys Res Commun. 433:420–425. 2013. View Article : Google Scholar : PubMed/NCBI
24	Xu Y, Li N, Xiang R and Sun P: Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci. 39:268–276. 2014. View Article : Google Scholar : PubMed/NCBI
25	Binet R, Ythier D, Robles AI, Collado M, Larrieu D, Fonti C, Brambilla E, Brambilla C, Serrano M, Harris CC, et al: WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. Cancer Res. 69:9183–9191. 2009. View Article : Google Scholar : PubMed/NCBI
26	Yu R, Zhang ZQ, Wang B, Jiang HX, Cheng L and Shen LM: Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation. Cancer Cell Int. 14:492014. View Article : Google Scholar : PubMed/NCBI
27	Zhang HH, Lipovsky AI, Dibble CC, Sahin M and Manning BD: S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell. 24:185–197. 2006. View Article : Google Scholar : PubMed/NCBI
28	Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
29	Ponnala S, Chetty C, Veeravalli KK, Dinh DH, Klopfenstein JD and Rao JS: MMP-9 silencing regulates hTERT expression via β1 integrin-mediated FAK signaling and induces senescence in glioma xenograft cells. Cell Signal. 23:2065–2075. 2011. View Article : Google Scholar : PubMed/NCBI
30	Noureini SK and Wink M: Antiproliferative effect of the isoquinoline alkaloid papaverine in hepatocarcinoma HepG-2 cells - inhibition of telomerase and induction of senescence. Molecules. 19:11846–11859. 2014. View Article : Google Scholar : PubMed/NCBI
31	Lai SR, Cunningham AP, Huynh VQ, Andrews LG and Tollefsbol TO: Evidence of extra-telomeric effects of hTERT and its regulation involving a feedback loop. Exp Cell Res. 313:322–330. 2007. View Article : Google Scholar : PubMed/NCBI
32	Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H and Inoue M: Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res. 6:1239–1247. 2000.PubMed/NCBI
33	Harada K, Kurisu K, Sadatomo T, Tahara H and Tahara E, Ide T and Tahara E: Growth inhibition of human glioma cells by transfection-induced P21 and its effects on telomerase activity. J Neurooncol. 47:39–46. 2000. View Article : Google Scholar : PubMed/NCBI